Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-690,550 plus mycophenolate versus cyclosporine-based immunosuppression in de novo kidney transplant recipients
2007-001984-31Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jun 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of tofacitinib, mycophenolate mofetil, mycophenolate sodium and cyclosporine in Acute renal rejection (ARR) (2 arms), sponsored by Pfizer. Primary endpoints: First clinical biopsy-proven acute rejection episode and Incidence of clinical biopsy-proven acute rejection at Month 6. Started Jun 2007; status: completed.
02
Drugs
03
Conditions
Acute renal rejection (ARR)
Beyond the preview
Go deeper on 2007-001984-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001984-31.